RESEARCH TRIANGLE PARK – Sheila Mikhail, a pioneer and thought leader in genetics and gene therapy, is stepping down as CEO of AskBio, a company she co-founded and later sold to global giant Bayer AG in 2020 for some $4 billion.
Mikhail will be replaced as CEO on March 11 by Gustavo Pesquin. His most recent position was chief commercial officer at Amneal Pharmaceuticals.
AskBio (full name Asklepios BioPharmaceutical) announced the changes Thursday.
Mikhail will remain a member of the AskBio board and also will have a part-time role as adviser/co-founder, the company said.
Gustavo Pesquin, Chief Executive Officer, AskBio (AskBio photo)
“In her new role, Mikhail will continue to support the strategic direction and growth of AskBio. She will also continue to support Columbus Children’s Foundation (CCF) in its development of gene therapies for ultra-rare diseases,” the company said.
RTP genetics firm AskBio to pursue more gene therapies in new partnership
